Literature DB >> 32051793

Refractory Renal Cell Cancer with Gastro-renal Fistula: A Rare Complication.

Eric Tam1, Elvira Neculiseanu1, Gurinder Sidhu1.   

Abstract

Metastatic renal cell cancer is treated with systemic therapy, and cytoreductive nephrectomy can be offered in selected patients. The systemic therapy treatment options for kidney cancer have now expanded to include tyrosine kinase inhibitors, monoclonal antibodies, immunotherapy, and combinations thereof. Cytoreductive nephrectomy is considered a safe surgery in most patients. Patients with advanced kidney cancer are known to develop several paraneoplastic syndromes and malignant cachexia. We present the case of a patient with renal cell cancer who was treated with tyrosine kinase inhibitors and despite treatment her disease progressed with subsequent increase in the renal cancer, which led to the development of a fistula between the renal mass and the stomach.
Copyright © 2020, Tam et al.

Entities:  

Keywords:  gastric fistula; kidney cancer

Year:  2020        PMID: 32051793      PMCID: PMC7001139          DOI: 10.7759/cureus.6580

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Kidney cancer.

Authors:  Robert J Motzer; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Michael A Carducci; Sam S Chang; Toni K Choueiri; Steven L Hancock; Gary R Hudes; Eric Jonasch; David Josephson; Timothy M Kuzel; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Philippe E Spiess; Jue Wang; Richard B Wilder
Journal:  J Natl Compr Canc Netw       Date:  2011-09-01       Impact factor: 11.908

3.  Cytoreductive Nephrectomy - Patient Selection Is Key.

Authors:  Robert J Motzer; Paul Russo
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

4.  Renoduodenal fistula after renal tumor ablation with radiofrequency.

Authors:  Homero O de Arruda; Suzan Goldman; Cássio Andreoni; Ronaldo S Maia; Jacob Szejnfeld; Valdemar Ortiz
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2006-10       Impact factor: 1.719

5.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

6.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Authors:  Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

7.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

8.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

9.  Germline BAP1 mutations predispose to renal cell carcinomas.

Authors:  Tatiana Popova; Lucie Hebert; Virginie Jacquemin; Sophie Gad; Virginie Caux-Moncoutier; Catherine Dubois-d'Enghien; Bénédicte Richaudeau; Xavier Renaudin; Jason Sellers; André Nicolas; Xavier Sastre-Garau; Laurence Desjardins; Gabor Gyapay; Virginie Raynal; Olga M Sinilnikova; Nadine Andrieu; Elodie Manié; Antoine de Pauw; Paul Gesta; Valérie Bonadona; Christine M Maugard; Clotilde Penet; Marie-Françoise Avril; Emmanuel Barillot; Odile Cabaret; Olivier Delattre; Stéphane Richard; Olivier Caron; Meriem Benfodda; Hui-Han Hu; Nadem Soufir; Brigitte Bressac-de Paillerets; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Am J Hum Genet       Date:  2013-05-16       Impact factor: 11.025

10.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.